fbpx
01 / 05
WHO Adds “Milestone” Malaria Vaccine to UN Procurement List

Health Policy Watch | Vaccination

WHO Adds “Milestone” Malaria Vaccine to UN Procurement List

“The World Health Organization (WHO) has added the R21/Matrix-M malaria vaccine to its list of ‘prequalified’ vaccines, paving the way for bulk procurement and mass deployment of the new vaccine across malaria-endemic countries by UNICEF and other global health agencies.

The prequalification of the world’s second malaria vaccine, developed by Oxford University and manufactured by Serum Institute of India (SII), is expected to greatly expand access to malaria vaccination, particularly in malaria endemic regions of sub-Saharan Africa where supplies of the already available RTS,S vaccine cannot alone meet the high demand, said WHO in a statement on Thursday.”

From Health Policy Watch.

NBC News | Vaccination

Chlamydia Vaccine Shows Promise in Early Trial

“An early-stage clinical trial yielded promising results for a chlamydia vaccine, researchers reported Thursday in The Lancet Infectious Diseases. 

There is currently no vaccine to protect against the sexually transmitted infection, which is the most common bacterial STI in the United States…

The phase 1 clinical trial, led by researchers in the United Kingdom and Denmark, found that the experimental vaccine was safe and induced an immune response.”

From NBC News.

The Daily Upside | Vaccination

Moderna Inches Nearer to Successful Cancer Vaccine

“Moderna has long touted that the mRNA vaccine technology it helped revolutionize during the global dash to create a coronavirus vaccine could be repurposed for a variety of medical uses. This vaccine, mRNA-4157, uses the method to train the immune system to identify and attack specific mutations in cancer cells.

The early-stage trial, conducted on patients already prescribed Merck’s Keytruda to treat certain types of head and neck cancer, produced some positive results — and hinted at an even brighter future for the vaccine.”

From The Daily Upside.

New Atlas | Treatment of Animals

Dog Cancer Vaccine Increases Survival Rates in Clinical Trial

“The researchers say that their canine cancer vaccine has almost doubled the 12-month survival rate for dogs with some types of cancer. For example, dogs with osteosarcoma have a 35% chance of living for one year after diagnosis when treated with chemotherapy and other conventional treatments, but the cancer vaccine boosted that to 60%.

Hunter, an 11-year-old golden retriever, is living proof. This search-and-rescue pup was diagnosed with osteosarcoma in his front left leg in 2022, but after an unfortunate amputation, chemotherapy and the new cancer vaccine, he’s reportedly living happy and energetic two years on.

The team is currently planning to conduct further studies to see if the cancer vaccine could be given to healthy dogs to prevent cancer forming in the first place, or to stop it earlier on.”

From New Atlas.